One Question, Multiple Answers: Biochemical and Biophysical Screening Methods Retrieve Deviating Fragment Hit Lists

Fragment‐based lead discovery is gaining momentum in drug development. Typically, a hierarchical cascade of several screening techniques is consulted to identify fragment hits which are then analyzed by crystallography. Because crystal structures with bound fragments are essential for the subsequent hit‐to‐lead‐to‐drug optimization, the screening process should distinguish reliably between binders and non‐binders. We therefore investigated whether different screening methods would reveal similar collections of putative binders. First we used a biochemical assay to identify fragments that bind to endothiapepsin, a surrogate for disease‐relevant aspartic proteases. In a comprehensive screening approach, we then evaluated our 361‐entry library by using a reporter‐displacement assay, saturation‐transfer difference NMR, native mass spectrometry, thermophoresis, and a thermal shift assay. While the combined results of these screening methods retrieve 10 of the 11 crystal structures originally predicted by the biochemical assay, the mutual overlap of individual hit lists is surprisingly low, highlighting that each technique operates on different biophysical principles and conditions.

[1]  Tom Blundell,et al.  The active site of aspartic proteinases , 1991, FEBS letters.

[2]  Michèle N Schulz,et al.  Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.

[3]  Dieter Braun,et al.  Molecular interaction studies using microscale thermophoresis. , 2011, Assay and drug development technologies.

[4]  D. Scott,et al.  Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.

[5]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[6]  Claudio Dalvit,et al.  Fluorine-NMR experiments for high-throughput screening: theoretical aspects, practical considerations, and range of applicability. , 2003, Journal of the American Chemical Society.

[7]  Jonathan Bard,et al.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. , 2004, Analytical biochemistry.

[8]  Olan Dolezal,et al.  Parallel Screening of Low Molecular Weight Fragment Libraries , 2013, Journal of biomolecular screening.

[9]  G. Klebe,et al.  Thermodynamic signatures of fragment binding: Validation of direct versus displacement ITC titrations. , 2015, Biochimica et biophysica acta.

[10]  Gerhard Müller,et al.  Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology , 2009, J. Comput. Aided Mol. Des..

[11]  B. Ganem,et al.  Detection of noncovalent receptor-ligand complexes by mass spectrometry , 1991 .

[12]  A. Dorsselaer,et al.  Nondenaturing mass spectrometry to study noncovalent protein/protein and protein/ligand complexes: technical aspects and application to the determination of binding stoichiometries. , 2008, Methods in molecular biology.

[13]  Glyn Williams,et al.  Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.

[14]  Gerhard Klebe,et al.  Tracing binding modes in hit-to-lead optimization: chameleon-like poses of aspartic protease inhibitors. , 2015, Angewandte Chemie.

[15]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[16]  Andrew L Hopkins,et al.  Fragment screening by surface plasmon resonance. , 2010, ACS medicinal chemistry letters.

[17]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[18]  C. Abell,et al.  A fragment-based approach to identifying ligands for riboswitches. , 2010, ACS chemical biology.

[19]  T Neumann,et al.  SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.

[20]  Kristin A. Sannes-Lowery,et al.  Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes , 2006, Nature Reviews Drug Discovery.

[21]  J. Whitaker,et al.  Endothia parasitica Protease. Parameters Affecting Stability of the Rennin-like Enzyme , 1970 .

[22]  Chris Abell,et al.  A three-stage biophysical screening cascade for fragment-based drug discovery , 2013, Nature Protocols.

[23]  Florian Pröll,et al.  Direct optical detection in fragment-based screening , 2009, Analytical and bioanalytical chemistry.

[24]  K Gubernator,et al.  Design and synthesis of potent and highly selective thrombin inhibitors. , 1994, Journal of medicinal chemistry.

[25]  D. Ringe,et al.  Locating and characterizing binding sites on proteins , 1996, Nature Biotechnology.

[26]  Harren Jhoti,et al.  High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.

[27]  Bernd Meyer,et al.  Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. , 1999, Angewandte Chemie.

[28]  C. Schalk-Hihi,et al.  Protein thermal shifts to identify low molecular weight fragments. , 2011, Methods in enzymology.

[29]  Gerhard Klebe,et al.  A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. , 2011, Journal of medicinal chemistry.

[30]  G. Klebe,et al.  Experimental and Computational Active Site Mapping as a Starting Point to Fragment‐Based Lead Discovery , 2012, ChemMedChem.

[31]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[32]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[33]  P. Śledź,et al.  High-Throughput Interrogation of Ligand Binding Mode Using a Fluorescence-Based Assay** , 2012, Angewandte Chemie.

[34]  B. Meyer,et al.  Charakterisierung von Ligandenbindung durch Sättigungstransfer‐Differenz‐NMR‐Spektroskopie , 1999 .

[35]  G. Fogliatto,et al.  WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability , 2001, Journal of biomolecular NMR.

[36]  D. Braun,et al.  Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. , 2013, Methods.

[37]  Jan Schultz,et al.  Integration of fragment screening and library design. , 2007, Drug discovery today.

[38]  Victor S. Lobanov,et al.  High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery , 2001 .

[39]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[40]  Wolfgang Jahnke,et al.  Fragment-based Approaches in Drug Discovery: JAHNKE: FRAGMENT-BASED APPROACHES IN DRUG DISCOVERY O-BK , 2006 .

[41]  D. Ullmann,et al.  HTS reporter displacement assay for fragment screening and fragment evolution toward leads with optimized binding kinetics, binding selectivity, and thermodynamic signature. , 2011, Methods in enzymology.

[42]  Wolfgang Jahnke and Daniel A. Erlanson Fragment-based approaches in drug discovery , 2013 .

[43]  T. O'Brien,et al.  Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.

[44]  H Roos,et al.  Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. , 2000, Journal of medicinal chemistry.

[45]  G. Klebe,et al.  Chamäleon‐artige Bindungsmodi in der Leitstrukturoptimierung: wechselnde Bindungsgeometrien bei Aspartylprotease‐Inhibitoren , 2015 .

[46]  Chris Abell,et al.  Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery , 2013, Proceedings of the National Academy of Sciences.

[47]  Claudio Dalvit,et al.  NMR methods in fragment screening: theory and a comparison with other biophysical techniques. , 2009, Drug discovery today.

[48]  A. van Dorsselaer,et al.  Native MS: an 'ESI' way to support structure- and fragment-based drug discovery. , 2010, Future medicinal chemistry.